Keith Haan
About Keith Haan
Keith Manchester, Director at Roivant
Keith Manchester has been serving as the Director of Roivant since 2014. He brings a wealth of experience in life sciences and finance, contributing to the strategic direction and growth of the company. His role involves overseeing various initiatives and ensuring the company meets its goals within the competitive biotechnology landscape.
Partner and Head of Life Sciences at QVT Financial
Keith Manchester also serves as a Partner and the Head of Life Sciences at QVT Financial in New York, USA. In this position, he focuses on investments in both publicly traded and privately owned life science companies, leveraging his expertise to identify promising opportunities and drive value for the firm's portfolio.
Education: Harvard College and Harvard Medical School
Keith Manchester received an A.B. from Harvard College, followed by an M.D. from Harvard Medical School. His academic background in these prestigious institutions provides him with a strong foundation in both life sciences and a strategic perspective on healthcare investments.
Professional Background in Biotechnology and Finance
Keith Manchester has an extensive background in biotechnology and finance. He was Vice President of Business Development from 2002 to 2004, and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. Prior to this, he worked as an associate at Vestar Capital Partners from 1999 to 2000, and as an investment banker in the healthcare group at Goldman, Sachs & Co. from 1997 to 1999.
Board Memberships and Supervisory Roles
In addition to his roles at Roivant and QVT Financial, Keith Manchester serves as a director for Arbutus Biopharma Corporation and Kriya Therapeutics. He also sits on the Supervisory Board of Medigene AG, further extending his influence and expertise across various sectors of the life sciences and biotechnology industries.